News | March 25, 2026
ImmunityBio scores first Asian approval for ANKTIVA in Macau
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
The facility features 2,176 high-performance GPUs across the US and Europe
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The endorsement follows overwhelming support for the share swap preceding the merger,
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
